Effectiveness and Safety of Drug-Eluting Stents in Ontario
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The placement of drug-eluting stents decreases the frequency of repeat revascularization procedures in patients undergoing percutaneous coronary intervention (PCI) in randomized clinical trials. However, there is uncertainty about the effectiveness of drug-eluting stents, and increasing concern about their safety, in routine clinical practice. METHODS: From the Cardiac Care Network of Ontario's population-based clinical registry of all patients undergoing PCI in Ontario, Canada, we identified a well-balanced cohort of 3751 pairs of patients, matched on the basis of propensity score, who received either bare-metal stents alone or drug-eluting stents alone during an index PCI procedure between December 1, 2003, and March 31, 2005. The primary outcomes of the study were the rates of target-vessel revascularization, myocardial infarction, and death. RESULTS: The 2-year rate of target-vessel revascularization was significantly lower among patients who received drug-eluting stents than among those who received bare-metal stents (7.4% vs. 10.7%, P<0.001). Drug-eluting stents were associated with significant reductions in the rate of target-vessel revascularization among patients with two or three risk factors for restenosis (i.e., presence of diabetes, small vessels [<3 mm in diameter], and long lesions [> or =20 mm]) but not among lower-risk patients. The 3-year mortality rate was significantly higher in the bare-metal-stent group than in the drug-eluting-stent group (7.8% vs. 5.5%, P<0.001), whereas the 2-year rate of myocardial infarction was similar in the two groups (5.2% and 5.7%, respectively; P=0.95). CONCLUSIONS: Drug-eluting stents are effective in reducing the need for target-vessel revascularization in patients at highest risk for restenosis, without a significantly increased rate of death or myocardial infarction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 15% of patients with T2DM will require target vessel revascularization within 2 years after bare metal stenting,290”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [290]
Citations
Cites
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Survival Analysis, Techniques for Censored and Truncated Data
Rao, M. B. (1998) · Technometrics · doi:10.1080/00401706.1998.10485206 · Cited by 3,617
Iakovou, I. (2005) · JAMA · doi:10.1001/jama.293.17.2126 · Cited by 3,132
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Stone, G. W., Moses, J. W., Ellis, S. G., Schofer, J., Dawkins, K. D., Morice, M.-C., Colombo, A., Schampaert, E., Grube, E., Kirtane, A. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067193 · Cited by 1,631
Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents
Pfisterer, M., Brunner-La Rocca, H. P., Buser, P. T., Rickenbacher, P., Hunziker, P., Mueller, C., Jeger, R., Bader, F., Osswald, S., & Kaiser, C. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.026 · Cited by 1,303
Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden
Lagerqvist, B., James, S. K., Stenestrand, U., Lindbäck, J., Nilsson, T., & Wallentin, L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067722 · Cited by 1,197
Grines, C. L., Bonow, R. O., Casey, D. E., Gardner, T. J., Lockhart, P. B., Moliterno, D. J., O’Gara, P., & Whitlow, P. (2007) · Circulation · doi:10.1161/circulationaha.106.180944 · Cited by 1,140
Austin, P. C., Grootendorst, P., & Anderson, G. M. (2007) · Statistics in Medicine · doi:10.1002/sim.2580 · Cited by 1,137
Self-citation
Research works printed but not linked: 1
- Wilkins R, 1993, Health Rep, 5, 157
Cited by
Palmerini, T., Biondi-Zoccai, G., Riva, D. D., Stettler, C., Sangiorgi, D., D'Ascenzo, F., Kimura, T., Briguori, C., Sabatè, M., Kim, H.-S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60324-9 · Cited by 959
Drug-Eluting Coronary-Artery Stents
Stefanini, G. G., & Holmes, D. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1210816 · Cited by 728
Kirtane, A. J., Gupta, A., Iyengar, S., Moses, J. W., Leon, M. B., Applegate, R., Brodie, B., Hannan, E., Harjai, K., Jensen, L. O., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.826479 · Cited by 577
Self-citationGarg, S., & Serruys, P. W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.007 · Cited by 501
Berger, M. L., Mamdani, M., Atkins, D., & Johnson, M. L. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00600.x · Cited by 409
“For example, rich clinical information for defined sets of patients can be merged into administrative data to limit the need for prospective follow-up of outcomes that are routinely collected in administrative datasets [ 30 ].”
BackgroundAntiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation
Kimura, T., Morimoto, T., Nakagawa, Y., Tamura, T., Kadota, K., Yasumoto, H., Nishikawa, H., Hiasa, Y., Muramatsu, T., Meguro, T., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.808311 · Cited by 358
Stettler, C., Allemann, S., Wandel, S., Kastrati, A., Morice, M. C., Schomig, A., Pfisterer, M. E., Stone, G. W., Leon, M. B., Lezo, J. S. D., et al. (2008) · BMJ · doi:10.1136/bmj.a1331 · Cited by 320
“For example, the rate of target lesion revascularisation at one year in patients who had undergone implantation of a bare metal stent in the TAXUS IV trial was 18.9% in those allocated to active follow-up and 14.3% in those allocated to regular clinical follow-up without mandatory angiography. The number needed to tre…”
BackgroundInfluentialCoronary stents: historical development, current status and future directions
Iqbal, J., Gunn, J., & Serruys, P. W. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt009 · Cited by 319
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Daemen, J., Boersma, E., Flather, M., Booth, J., Stables, R., Rodriguez, A., Rodriguez-Granillo, G., Hueb, W. A., Lemos, P. A., & Serruys, P. W. (2008) · Circulation · doi:10.1161/circulationaha.107.752147 · Cited by 300
A Review of Propensity-Score Methods and Their Use in Cardiovascular Research
Deb, S., Austin, P. C., Tu, J. V., Ko, D. T., Mazer, C. D., Kiss, A., & Fremes, S. E. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.05.015 · Cited by 275
Self-citationDrug-Eluting versus Bare-Metal Stents in Large Coronary Arteries
Kaiser, C., Galatius, S., Erne, P., Eberli, F., Alber, H., Rickli, H., Pedrazzini, G., Hornig, B., Bertel, O., Bonetti, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009406 · Cited by 267
Drug-Eluting or Bare-Metal Stents for Acute Myocardial Infarction
Mauri, L., Silbaugh, T. S., Garg, P., Wolf, R. E., Zelevinsky, K., Lovett, A., Varma, M. R., Zhou, Z., & Normand, S.-L. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801485 · Cited by 245
Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in Sweden
James, S. K., Stenestrand, U., Lindbäck, J., Carlsson, J., Scherstén, F., Nilsson, T., Wallentin, L., & Lagerqvist, B. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809902 · Cited by 237
Cardiac Risk of Noncardiac Surgery after Percutaneous Coronary Intervention with Drug-eluting Stents
Rabbitts, J. A., Nuttall, G. A., Brown, M. J., Hanson, A. C., Oliver, W. C., Holmes, D. R., & Rihal, C. S. (2008) · Anesthesiology · doi:10.1097/aln.0b013e318186de1c · Cited by 221
“Drug-eluting stents reduce the rates of repeat target vessel revascularization or coronary artery bypass grafting surgery.(3,4) DESs effectively reduce neointimal proliferation and rates of angiographic restenosis; however, the same drugs delay stent endothelialization,(5,6) thus potentially prolonging the period wher…”
BackgroundRasmussen, K., Maeng, M., Kaltoft, A., Thayssen, P., Kelbæk, H., Tilsted, H. H., Abildgaard, U., Christiansen, E. H., Engstrøm, T., Krusell, L. R., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60208-5 · Cited by 212
Tu, J. V., Chu, A., Donovan, L. R., Ko, D. T., Booth, G. L., Tu, K., Maclagan, L. C., Guo, H., Austin, P. C., Hogg, W., et al. (2015) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.001416 · Cited by 187
“In addition, Ontario has several population-based cardiovascular and stroke registries that can be used to further our understanding of cardiovascular events and the transition between hospitals and ambulatory care settings.(23,33,34) We also foresee unique opportunities to leverage these data sets to develop novel cl…”
BackgroundSelf-citationRisk of Elective Major Noncardiac Surgery After Coronary Stent Insertion: A Population-Based Study
Wijeysundera, D. N., Wijeysundera, H. C., Yun, L., Wąsowicz, M., Beattie, W. S., Velianou, J. L., & Ko, D. T. (2012) · Circulation · doi:10.1161/circulationaha.112.102715 · Cited by 169
“The Cardiac Care Network of Ontario serves as a support to the Ontario health care system, including the Ontario Ministry of Health and Long-Term Care, and is dedicated to improving the quality, efficiency, access, and equity of adult cardiovascular services in Ontario, Canada.”
Self-citationClinical Effectiveness of Coronary Stents in Elderly Persons
Douglas, P. S., Brennan, J. M., Anstrom, K. J., Sedrakyan, A., Eisenstein, E. L., Haque, G., Dai, D., Kong, D. F., Hammill, B. G., Curtis, L. H., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.005 · Cited by 147
Long-Term Clinical Outcomes Following Drug-eluting and Bare Metal Stenting in Massachusetts
Mauri, L., Silbaugh, T. S., Wolf, R., Zelevinsky, K., Lovett, A. F., Zhou, Z., Resnic, F. S., & Normand, S. (2008) · Circulation · doi:10.1161/circulationaha.108.781377 · Cited by 152
Valgimigli, M., Tebaldi, M., Borghesi, M., Vranckx, P., Campo, G. C., Tumscitz, C., Cangiano, E., Minarelli, M., Scalone, A., Cavazza, C., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.09.008 · Cited by 136
“Randomized, controlled trials (1,2), meta-analyses (3), and observational studies (4) have consistently shown reduced rates of angiographic restenosis and ischemia-driven target vessel revascularization (TVR) with drug-eluting stents (DES) compared with bare-metal stents (BMS).”
BackgroundStafinski, T., McCabe, C. J., & Menon, D. (2010) · PharmacoEconomics · doi:10.2165/11530820-000000000-00000 · Cited by 136
Safety and Efficacy of Drug-Eluting Stents in Older Patients With Chronic Kidney Disease
Tsai, T. T., Messenger, J. C., Brennan, J. M., Patel, U. D., Dai, D., Piana, R. N., Anstrom, K. J., Eisenstein, E. L., Dokholyan, R. S., Peterson, E. D., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.056 · Cited by 128
Muscle Glycogenosis Due to Phosphoglucomutase 1 Deficiency
Stojkovic, T., Vissing, J., Petit, F. M., Piraud, M., Ørngreen, M. C., Andersen, G., Claeys, K. G., Wary, C., Hogrel, J., & Laforêt, P. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0901158 · Cited by 117
Multivessel Coronary Revascularization in Patients With and Without Diabetes Mellitus
Daemen, J., Kück, K., Macaya, C., Legrand, V. M. G., Vrolix, M., Carrié, D., Sheiban, I., SUTTORP, M. J., Vranckx, P., Rademaker, T., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.010 · Cited by 117
Administrative Hospitalization Database Validation of Cardiac Procedure Codes
Lee, D. S., Stitt, A., Wang, X., Yu, J. S., Gurevich, Y., Kingsbury, K., Austin, P. C., & Tu, J. V. (2011) · Medical Care · doi:10.1097/mlr.0b013e3182329778 · Cited by 114
“Data in the CCN database were collected prospectively by regional nurse coordinators, who directly received referral information.(8)”
MethodSelf-citationAcute coronary syndrome in the Asia-Pacific region
Chan, M. Y., Du, X., Eccleston, D. S., Ma, C., Mohanan, P. P., Ogita, M., Shyu, K., Yan, B. P., & Jeong, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.073 · Cited by 128
Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents
Malenka, D. J., Kaplan, A. V., Lucas, F. L., Sharp, S. M., & Skinner, J. S. (2008) · JAMA · doi:10.1001/jama.299.24.2868 · Cited by 110
Kimura, T., Morimoto, T., Furukawa, Y., Nakagawa, Y., Kadota, K., Iwabuchi, M., Shizuta, S., Shiomi, H., Tada, T., Tazaki, J., et al. (2011) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-011-0065-0 · Cited by 108
“Consistent with previous reports from the observational registries, a survival benefit of DES over BMS was also seen in this study [5–9].”
BackgroundResult“Dose-dependent” Impact of Recurrent Cardiac Events on Mortality in Patients with Heart Failure
Lee, D. S., Austin, P. C., Stukel, T. A., Alter, D. A., Chong, A. S., Parker, J. D., & Tu, J. V. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.08.026 · Cited by 109
Self-citationPfisterer, M. E., Rocca, H. B., Rickenbacher, P. R., Hunziker, P., Mueller, C. E., Nietlispach, F., Leibundgut, G., Bader, F., Kaiser, C. A., & for the BASKET Investigators (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn516 · Cited by 102
“Still, conflicting results from registries regarding longer-term mortality or cardiac death/non-fatal myocardial infarction (MI) rates were published.(2,3,7,8,10,11) A sophisticated analysis of the BASKET 18-month data defining predictors of outcome and their interaction with stent type identified a subgroup of patien…”
ResultChan, W., Clark, D., Ajani, A. E., Yap, C., Andrianopoulos, N., Brennan, A., Dinh, D. T., Shardey, G. C., Smith, J. A., Reid, C. M., et al. (2010) · Heart Lung and Circulation · doi:10.1016/j.hlc.2010.10.002 · Cited by 97
Applegate, R. J., Sacrinty, M. T., Kutcher, M. A., dos Santos, R. M., Gandhi, S. K., Baki, T. T., & Little, W. C. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.08.064 · Cited by 95
Byrne, R. A., Schulz, S., Mehilli, J., Iijima, R., Maßberg, S., Neumann, F., Berg, J. M. T., Schömig, A., & Kastrati, A. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.12.019 · Cited by 93
Association of Maternal Age With Severe Maternal Morbidity and Mortality in Canada
Aoyama, K., Pinto, R. L., Ray, J. G., Hill, A. D., Scales, D. C., Lapinsky, S. E., Hladunewich, M., Seaward, G. R., & Fowler, R. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.9875 · Cited by 110
Coverage with Evidence Development: Applications and issues
Trueman, P., Grainger, D. L., & Downs, K. E. (2010) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462309990882 · Cited by 93
“In Ontario, Canada, an observational study was conducted to compare drug-eluting stents (DES) and bare metal stents (BMS) in an observational study using propensity score matched patients (15).”
BackgroundKo, D. T., Guo, H., Wijeysundera, H. C., Natarajan, M. K., Nagpal, D., Feindel, C. M., Kingsbury, K., Cohen, E. A., & Tu, J. V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.056 · Cited by 94
Self-citationKim, Y., Park, D., Lee, S., Yun, S., Lee, C. W., Hong, M., Park, S., Seung, K. B., Gwon, H., Jeong, M. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.800805 · Cited by 91
Valgimigli, M., Sabaté, M., Kaiser, C., Brugaletta, S., Hernández, J., Galatius, S., Cequier, A. R., Eberli, F. R., de Belder, A., Serruys, P. W. J. C., et al. (2014) · BMJ · doi:10.1136/bmj.g6427 · Cited by 92
Stone, G. W., Parise, H., Witzenbichler, B., Kirtane, A. J., Guagliumi, G., Peruga, J. Z., Brodie, B. R., Dudek, D., Möckel, M. M., Lansky, A. J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.08.608 · Cited by 89
Park, D., Yun, S., Lee, S., Kim, Y., Lee, C. W., Hong, M., Cheong, S., Kim, J., Park, S., & Park, S. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.06.011 · Cited by 86
Anderson, M. L., Peterson, E., Brennan, J. M., Rao, S. V., Dai, D., Anstrom, K., Piana, R., Popescu, A. M., Sedrakyan, A., Messenger, J., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.111369 · Cited by 93
Ko, D. T., Tu, J. V., Samadashvili, Z., Guo, H., Alter, D. A., Cantor, W. J., & Hannan, E. L. (2010) · Circulation · doi:10.1161/circulationaha.109.926881 · Cited by 83
Self-citationKo, D. T., Tu, J. V., Austin, P. C., Wijeysundera, H. C., Samadashvili, Z., Guo, H., Cantor, W. J., & Hannan, E. L. (2013) · JAMA · doi:10.1001/jama.2013.7834 · Cited by 85
Self-citationCardiovascular Outcomes after a Change in Prescription Policy for Clopidogrel
Jackevicius, C. A., Tu, J. V., Demers, V., de Melo, M. N., Cox, J. L., Rinfret, S., Kalavrouziotis, D., Johansen, H., Behlouli, H., Newman, A. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0803410 · Cited by 81
Self-citationLate Adverse Events After Implantation of Sirolimus-Eluting Stent and Bare-Metal Stent
Natsuaki, M., Morimoto, T., Furukawa, Y., Nakagawa, Y., Kadota, K., Yamaji, K., Andò, K., Shizuta, S., Shiomi, H., Tada, T., et al. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.113.000987 · Cited by 78
Ko, D. T., Yun, L., Wijeysundera, H. C., Jackevicius, C. A., Rao, S. V., Austin, P. C., Marquis, J.-F., & Tu, J. V. (2010) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.928721 · Cited by 75
Self-citationNumber needed to treat is incorrect without proper time-related considerations
Suissa, D., Brassard, P., Smiechowski, B., & Suissa, S. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.04.009 · Cited by 73
Quantifying Health Services Use for Chronic Obstructive Pulmonary Disease
Gershon, A. S., Guan, J., Victor, J. C., Goldstein, R. S., & To, T. M. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201211-2044oc · Cited by 82
Outcomes and Complications With Off-Label Use of Drug-Eluting Stents
Brodie, B. R., Stuckey, T., Downey, W. E., Humphrey, A. D., Bradshaw, B. H., Metzger, C., Hermiller, J. B., Krainin, F. M., Juk, S., Cheek, B., et al. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.06.005 · Cited by 70
Lee, C. W., Park, D., Lee, S., Kim, Y., Hong, M., Kim, J., Park, S., Yun, S., Seong, I. W., Lee, J., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.06.059 · Cited by 68
Drug-Eluting Stents in Percutaneous Coronary Intervention
Byrne, R. A., Sarafoff, N., Kastrati, A., & Schömig, A. (2009) · Drug Safety · doi:10.2165/11316500-000000000-00000 · Cited by 68
“001).([92]) A Cleveland Clinic registry (OH, USA) analysis (n = 8032) reported that despite extensive adjustment for multiple confounders, DES was associated with significant mortality reduction compared with BMS (0.”
Leone, A. M., Scalone, G., Maria, G. L. D., Tagliaferro, F., Gardi, A., Clemente, F., Basile, E., Cialdella, P., Caterina, A. R. D., Porto, I., et al. (2015) · EuroIntervention · doi:10.4244/eijy14m07_02 · Cited by 68
Kaltoft, A., Jensen, L. O., Mæng, M., Tilsted, H. H., Thayssen, P., Bøttcher, M., Lassen, J. F., Krusell, L. R., Rasmussen, K., Hansen, K. N., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.058 · Cited by 66
The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts
Steigerwald, K., Merl, S., Kastrati, A., Wieczorek, A., Vorpahl, M., Mannhold, R., Vogeser, M., Hausleiter, J., Joner, M., Schömig, A., et al. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.10.005 · Cited by 66
“Regarding the pharmacologic compound, rapamycin appears to be associated with a high level of enduring efficacy and safety in clinical studies, regardless whether tested in randomized controlled trials [20] or observational studies [21].”
BackgroundYeh, R. W., Normand, S.-L. T., Wolf, R. E., Jones, P. G., Ho, K. K. L., Cohen, D. J., Cutlip, D. E., Mauri, L., Kugelmass, A. D., Amin, A. P., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.045229 · Cited by 63
Survivor treatment bias, treatment selection bias, and propensity scores in observational research
Austin, P. C., & Platt, R. W. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.05.009 · Cited by 63
“[12] Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, et al.”
BackgroundSelf-citationStenestrand, U., James, S. K., Lindbäck, J., Fröbert, O., CARLSSON, J., Scherstén, F., Nilsson, T., Lagerqvist, B., & for the SCAAR/SWEDEHEART study group (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp424 · Cited by 62
Lee, D. S., Ghosh, N., Floras, J. S., Newton, G. E., Austin, P. C., Wang, X., Liu, P. P., Stukel, T. A., & Tu, J. V. (2009) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.869743 · Cited by 61
Self-citationAppleby, C. E., Ivanov, J., Lavi, S., Mackie, K., Horlick, E. M., Ing, D. J., Overgaard, C. B., Seidelin, P. H., von Harsdorf, R., & Džavík, V. (2009) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.108.828954 · Cited by 58
Amin, A. P., Spertus, J. A., Cohen, D. J., Chhatriwalla, A., Kennedy, K. F., Vilain, K., Salisbury, A. C., Venkitachalam, L., Lai, S. M., Mauri, L., et al. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.3093 · Cited by 58
“Tu and colleagues 8 found that in Ontario’s Cardiac Care Network, the benefits of DES were substantially greater in those patients with diabetes, small target vessels [ (cid:2) 3 mm in diameter], and long lesions [stent length (cid:4) 20 mm].”
BackgroundWijeysundera, H. C., Trubiani, G., Wang, X., Mitsakakis, N., Austin, P. C., Ko, D. T., Lee, D. S., Tu, J. V., & Krahn, M. D. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.971051 · Cited by 56
“We then created a propensity-score–matched cohort by matching each patient in the HF clinic cohort with one in the control cohort (a 1:1 match).(9,10) A greedy nearest-neighbor–matching algorithm was used to match each HF clinic patient to the nearest control patient on the basis of the logit of their propensity-score…”
BackgroundMethodInfluentialSelf-citationLong-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis
Alfonso, F., Pérez-Vizcayno, M.-J., Hernández, R., Bethencourt, A., Vicens Martí, C., López-Mínguez, J. R., Angel, J. G. D., Íñiguez, A., Morı́s, C., Cequier, A. R., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.025 · Cited by 55
D’Ascenzo, F., Cavallero, E., Biondi‐Zoccai, G., Moretti, C., Omedè, P., Bollati, M., Castagno, D., Modena, M. G., Gaïta, F., & Sheiban, I. (2012) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2012.00753.x · Cited by 54
Ryan, J. W., Linde‐Zwirble, W. T., Engelhart, L., Cooper, L. M., & Cohen, D. J. (2009) · Circulation · doi:10.1161/circulationaha.108.781138 · Cited by 52
“CABG 166 145 ( 21 ) (12.7) PCI 268 345 77 28.7 Total 434 490 56 12.9”
InfluentialChan, W., Ivanov, J., Ko, D. T., Fremes, S. E., Rao, V., Jolly, S. S., Cantor, W. J., Lavi, S., Overgaard, C. B., Ruel, M., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001973 · Cited by 53
“All patients’ data were obtained from the Cardiac Care Network of Ontario Cardiac Registry, which prospectively records patient information related to their demographics, clinical presentation, and procedural variables in those undergoing cardiac catheterization and revascularization procedures.(24,25) The Cardiac Car…”
MethodSelf-citationKo, D. T., Chiu, M., Guo, H., Austin, P. C., Goeree, R. A., Cohen, E. A., Labinaz, M. X., & Tu, J. V. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.059 · Cited by 51
Self-citationNovel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial
Briguori, C., Airoldi, F., Visconti, G., Focaccio, A., Caiazzo, G., Golia, B., Biondi‐Zoccai, G., Ricciardelli, B., & Condorelli, G. (2011) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.110.959924 · Cited by 46
Maron, D. J., Spertus, J. A., Mancini, G. B. J., Hartigan, P. M., Sedlis, S. P., Bates, E., Kostuk, W. J., Dada, M. R., Berman, D. S., Shaw, L. J., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.056 · Cited by 46
Current Status of Drug-Eluting Stents
Räber, L., & Windecker, S. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00144.x · Cited by 45
“0001) at 2 years in a case-matched study from Ontario [6], and to 4.”
BackgroundLong-term clinical outcomes and predictors for survivors of out-of-hospital cardiac arrest
Shuvy, M., Morrison, L. J., Koh, M., Qiu, F., Buick, J. E., Dorian, P., Scales, D. C., Tu, J. V., Verbeek, P. R., Wijeysundera, H. C., et al. (2017) · Resuscitation · doi:10.1016/j.resuscitation.2016.12.026 · Cited by 52
Self-citationAoyama, K., Pinto, R. L., Ray, J. G., Hill, A. D., Scales, D. C., Lapinsky, S. E., Hladunewich, M., Seaward, G. R., & Fowler, R. (2019) · Critical Care · doi:10.1186/s13054-019-2660-x · Cited by 54
Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality
Shishehbor, M. H., Goel, S. S., Kapadia, S. R., Bhatt, D. L., Kelly, P. J., Raymond, R. E., Galla, J. M., Brener, S. J., Whitlow, P. L., & Ellis, S. G. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.030 · Cited by 46
de Waha, A., Dibra, A., Kufner, S., Baumgart, D., Sabaté, M., Maresta, A., Schömig, A., & Kastrati, A. (2011) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0278-8 · Cited by 42
“Our findings demonstrate the high effectiveness of sirolimus-eluting stents in diabetic patients which is in line with recent findings on the effectiveness of drugeluting stents in patients at highest risk for restenosis [31–33].”
ResultCarbonylation of Runx2 at K176 by 4-Hydroxynonenal Accelerates Vascular Calcification
Zhai, X., Cao, S., Wang, J., Qiao, B., Liu, X., Hua, R., Zhao, M., Sun, S., Han, Y., Wu, S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065830 · Cited by 44
“29 The propensity score for the predicted probability of vascular calcification was estimated with the use of a logistic-regression model fit with demographics (age, sex, and body mass index), clinical characteristics (heart rate, systolic blood pressure, and cigarette smoking) and medical history…”
MethodImportance of Nonobstructive Coronary Artery Disease in the Prognosis of Patients With Heart Failure
Braga, J. R., Austin, P. C., Ross, H. J., Tu, J. V., & Lee, D. S. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.02.014 · Cited by 48
Self-citationCoronary Stents: The Impact of Technological Advances on Clinical Outcomes
Mennuni, M. G., Pagnotta, P. A., & Stefanini, G. G. (2015) · Annals of Biomedical Engineering · doi:10.1007/s10439-015-1399-z · Cited by 42
Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use
Venkitachalam, L., Lei, Y., Stolker, J. M., Mahoney, E. M., Amin, A. P., Lindsey, J. B., Kennedy, K. F., Pencina, M. J., López, J. J., Kleiman, N. S., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.978593 · Cited by 42
Coverage with evidence development: The Ontario experience
Levin, L., Goeree, R. A., Levine, M. N., Krahn, M. D., Easty, T., Brown, A., & Henry, D. A. (2011) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462311000018 · Cited by 48
“Restenosis rates were similar for BMS and DES for low-risk patients, whereas high risk patients with narrow or long lesions with diabetes were found to derive benefit from DES (26).”
BackgroundMethodInfluentialSelf-citationRamana, R. K., Ronan, A., Cohoon, K. P., Homan, D. J., Sutherland, J. A., Steen, L., Liu, J., Loeb, H. S., & Lewis, B. (2008) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.21552 · Cited by 40
Usage patterns and 2‐year outcomes with the TAXUS express stent: Results of the US ARRIVE 1 registry
Lasala, J. M., Cox, D. A., Dobies, D., Muhlestein, J. B., Katopodis, J., Revtyak, G. E., & Baim, D. S. (2008) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.21618 · Cited by 40
“Likewise, findings from the Ontario registry (in which 83% of the 3751 DES were TAXUS) showed similar mortality, which was significantly reduced compared with a propensity-score matched group of 3,751 BMS patients [15].”
ResultCalculation of Number Needed to Treat
Suissa, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0903274 · Cited by 40
Off-Label Use of Drug-Eluting Stents
Grines, C. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.028 · Cited by 39
Shimizu, T., Ohno, T., Ando, J., Fujita, H., Nagai, R., Motomura, N., Ōno, M., Kyo, S., & Takamoto, S. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0586 · Cited by 38
Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007
members:, A., Daemen, J., Simoons, M. L., Wijns, W., Bagust, A., Bos, G., Bowen, J. M., D, E. B. M., Camenzind, E., Chevalier, B., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn510 · Cited by 37
“Drug-eluting stents (DES) were introduced into clinical practice in 2002 in order to reduce restenosis that occurred in 15–25% of patients receiving bare-metal stents (BMS).1– 3 Subsequent trials with different types of DES confirmed their efficacy in this regard.4 However, late stent thrombosis was reported as early…”
BackgroundInfluentialSelf-citationGreenwood, B. N., Agarwal, R., Agarwal, R., & Gopal, A. (2017) · Management Sciences · doi:10.1287/mnsc.2016.2490 · Cited by 30
“However, because these studies, which either substantiate or refute the guideline (Boden et al. 2007, Lüscher et al. 2007, Tu et al. 2007), were released after the guideline we do not believe they contaminate our analysis.”
Menozzi, A., Solinas, E., Ortolani, P., Repetto, A., Saia, F., Piovaccari, G., Manari, A., Magagnini, E., Vignali, L., Bonizzoni, E., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp224 · Cited by 35
Acceptance, Panic, and Partial Recovery
Krone, R. J., Rao, S. V., Dai, D., Anderson, H. V., Peterson, E. D., Brown, M., Brindis, R. G., Klein, L. W., Shaw, R. E., & Weintraub, W. S. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.06.014 · Cited by 35
Short-term outcomes from drug-coated balloon for coronary de novo lesions in large vessels
Lu, W., Zhu, Y., Han, Z., Sun, G., Qin, X., Wang, Z., Liu, G., Wang, X., Wang, X., Pan, L., et al. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.07.008 · Cited by 35
Ko, D. T., Chiu, M., Guo, H., Austin, P. C., Marquis, J.-F., & Tu, J. V. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.06.030 · Cited by 38
Self-citationLasala, J. M., Cox, D. A., Lewis, S. J., Tadros, P., Haas, R., Schweiger, M. J., Chhabra, A., Untereker, W. J., Starzyk, R. M., Mascioli, S. R., et al. (2009) · EuroIntervention · doi:10.4244/eijv5i1a11 · Cited by 35
Geri, G., Scales, D., Koh, M., Wijeysundera, H., Lin, S., Feldman, M., Cheskes, S., Dorian, P., Isaranuwatchai, W., Morrison, L., et al. (2020) · Resuscitation · doi:10.1016/j.resuscitation.2020.04.032 · Cited by 26
Self-citationYan, B. P., Duffy, S. J., Clark, D. J., Lefkovits, J., Warren, R., Gurvitch, R., Lew, R., Sebastian, M., Brennan, A., Andrianopoulos, N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.058 · Cited by 34
Long‐Term Clinical Outcomes of the Drug‐Eluting Stents in the Real World (DESIRE) Registry
Sousa, A., Costa, J. R., Moreira, A. C., Cano, M. N., Maldonado, G. A., da Costa, R. A., Pavanello, R., Romano, E. R., Campos, C., Haddad, N., et al. (2008) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2008.00379.x · Cited by 32
Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On- and Off-Label Criteria
CARLSSON, J., James, S. K., Lindbäck, J., Scherstén, F., Nilsson, T., Stenestrand, U., & Lagerqvist, B. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.067 · Cited by 32
van Twisk, P.-H., Daemen, J., Kukreja, N., van Domburg, R. T., & Serruys, P. W. J. C. (2008) · EuroIntervention · doi:10.4244/eijv4i3a57 · Cited by 32
Drug-eluting stents: a reappraisal
Garg, S., & Serruys, P. W. J. C. (2010) · Heart · doi:10.1136/hrt.2009.189522 · Cited by 30
“In addition to the acute presentation, outcomes for PCI in patients with in-stent restenosis are poorer than PCI for de novo lesions. A mortality rate of 2.5% was reported in the Ontario registry in those having TVR within a month of BMS implantation,”
BackgroundInfluentialJensen, L. O., Mæng, M., Thayssen, P., Kaltoft, A., Tilsted, H. H., Bøttcher, M., Lassen, J. F., Hansen, K. N., Krusell, L. R., Rasmussen, K., et al. (2008) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.108.794578 · Cited by 31
Poder, T. G., Erraji, J., Coulibaly, L. P., & Koffi, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177476 · Cited by 31
Survival Benefit With Drug-Eluting Stents in Observational Studies: Fact or Artifact?
Venkitachalam, L., Lei, Y., Magnuson, E. A., Chan, P. S., Stolker, J. M., Kennedy, K. F., Kleiman, N. S., & Cohen, D. J. (2011) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.960971 · Cited by 32
Metadata
- Authors
- Tu, J. V., Bowen, J., Chiu, M., Ko, D. T., Austin, P. C., He, Y., Hopkins, R., Tarride, J.-E., Blackhouse, G., Lazzam, C., Cohen, E. A., & Goeree, R.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Institute for Clinical Evaluative Sciences (CA)
- Trillium Health Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-10-04
- Volume
- 357
- Issue
- 14
- Pages
- 1393-1402
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2082511254
- Cited by
- 383
- References
- 35
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 11 · 2019: 7 · 2018: 5 · 2017: 13 · 2016: 15 · 2015: 28 · 2014: 15 · 2013: 15 · 2012: 34
- FWCI
- 67.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- drug-eluting stents, bare-metal stents, percutaneous coronary intervention, target vessel revascularization, restenosis, myocardial infarction, mortality, diabetes mellitus, long coronary lesions, propensity score matching, clinical registries, Ontario
- MeSH terms
- Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Ontario, Prosthesis Design, Registries, Risk Factors, Stents, Angioplasty, Balloon, Coronary, Drug Delivery Systems, Myocardial Ischemia, Disease-Free Survival, Coronary Restenosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.